News

EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...
Medical Dialogues1d
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Pharmabiz2d
EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older
EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...
GSK applies to EU regulator for expanded use of RSV vaccine
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK's RSV drug Arexvy accepted for regulatory review in Europe
Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...
GSK's RSV vaccine accepted for regulatory review by EMA
Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...
Business Wire7mon
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...
Healthline10mon
Arexvy and Cost: What You Need to Know
Arexvy is a vaccine used to prevent certain lower respiratory infections caused by respiratory syncytial virus (RSV). Arexvy’s cost may depend on factors such as whether you have health ...
Yahoo Finance1y
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is ...
FiercePharma1y
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun
While taking its victory lap and predicting a peak sales projection of 3 billion pounds ($3.8 billion) for Arexvy, GSK recognizes that the market is evolving and that its fast start in RSV is no ...
Business Wire1y
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Vaccine efficacy of a single dose against RSV-LRTD after two seasons and vaccine efficacy after annual revaccination were confirmatory secondary endpoints. About AREXVY (respiratory syncytial ...
Medindia2y
Arexvy: The First Respiratory Syncitial Virus (RSV) Vaccine Approved by FDA
Arexvy is the first FDA-approved Respiratory Syncitial Virus (RSV) vaccine It has a high efficacy with a 94.6% effectiveness rate in persons with underlying illnesses This breakthrough is expected ...